TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19656025
Drug: Full-mouth ultrasonic
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth ultrasonic debridement + amoxicillin and metronidazole
Study: 14739186
Drug: Recombinant follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle stimulating hormone
Study: 14739186
Drug: Electrocautery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone
Study: 9129894
Drug: 15,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15,000 IU of heparin (group A)
Study: 9129894
Drug: 100 IU.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU.kg‐1 of heparin (group B)
Study: 7961027
Drug: Thermoradiotherapy (HTRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoradiotherapy (HTRT) with regional hyperthermia and radiotherapy, total dose ranged from 42 to 80 Gy (mean 62.9 Gy) for definitive treatment, and 38 to 47 Gy (mean 40.6 Gy) for preoperative cases. Radiofrequency capacitive hyperthermia was administered twice weekly, with total sessions ranging from 5 to 16 (mean 9.0) for definitive treatment and 3 to 8 (mean 6.7) for preoperative cases.
Study: 31959233
Drug: Lifestyle physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle physical activity group (LPAG) aiming to increase daily physical activity and reduce sedentary behaviour for 12 weeks
Study: 29358714
Drug: Disulfiram treatment
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment in AD model mice
Study: 29358714
Drug: Disulfiram treatment
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment in SH-SY5Y human neuronal cells
Study: 29358714
Drug: Disulfiram treatment
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment in alcohol-dependent patients
Study: 24572041
Drug: Lupin kernel
Normalized name: palm kernelate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin kernel fiber (LF) 25-g/d
Study: 20107202
Drug: LRPT 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRPT 50 mg
Study: 20107202
Drug: LRPT 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRPT 600 mg
Study: 17352635
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (7 joules/2 min) over the carpal tunnel area, 41 patients
Study: 17352635
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy, 40 patients
Study: 9810742
Drug: Experimental design
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental design (e.g. randomized clinical trial)
Study: 7824087
Drug: Erythromycin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3.5 mg/kg bolus injection)
Study: 3277488
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate ointment (100 mg tid)
Study: 29925328
Drug: Gabapentin oral
Normalized name: gabapentin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin oral solution (5 mg/kg in 5 ml strawberry juice)
Study: 29925328
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of oral strawberry juice)
Study: 18768528
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Study: 18768528
Drug: Intravenous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Study: 20613670
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day for 6 months
Study: 11930704
Drug: Inhaled Beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Beclomethasone dipropionate (BDP) 200 micrograms/d
Study: 11930704
Drug: Inhaled Beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Beclomethasone dipropionate (BDP) 400 micrograms/d
Study: 3345619
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg alprazolam plus saline infusion
Study: 3345619
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg alprazolam plus saline
Study: 3345619
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg plus 72 micrograms alprazolam/hr for a total dose of 1.576 mg in 8 hours
Study: 3345619
Drug: Placebo (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50% propylene glycol injection followed by saline infusion)
Study: 30638420
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of commercial pasteurized orange juice for 2 months
Study: 12580655
Drug: Ribose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose supplementation (32 g, 4 x 8-g doses)
Study: 18320520
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravitreal bevacizumab
Study: 18662829
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravitreal triamcinolone
Study: 26210303
Drug: Active tVNS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tVNS (daily active stimulation of the left auricle for 26 weeks)
Study: 26210303
Drug: Sham tVNS
Normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tVNS (daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation)
Study: 22024002
Drug: Another SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another SSRI + cognitive behavior therapy (CBT)
Study: 19729392
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE)-based therapies
Study: 17664205
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg x kg(‐1) bolus prior to sternotomy, followed by 1 mg x kg(‐1) x hr(‐1) infusion)
Study: 8215672
Drug: Direct infusion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct infusion
Study: 9683306
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg day(-1))
Study: 9683306
Drug: Norethisterone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone (2.5 mg day(-1) for 21 days out of 28 for three cycles)
Study: 18157412
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion
Study: 3387033
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone and high-dose metoclopramide (regimen A)
Study: 3387033
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone and sulpiride (regimen B)
Study: 27720403
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg calcitriol
Study: 27720403
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium carbonate + 25 μg calcitriol
Study: 22886138
Drug: Polidocanol (POL)
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol (POL) micro-foam injection
Study: 22886138
Drug: Laser after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser after POL injection
Study: 15265408
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg (group RE, n = 15)
Study: 10421125
Drug: Enflurane administration
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane administration (0.5% to 2%) for 5 minutes
Study: 10421125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no enflurane administration)
Study: 7554976
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of contraceptive pill for 21 days with a seven-day interruption (intermittent use)
Study: 7554976
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of contraceptive pill without interruption (continuous use)
Study: 6158370
Drug: Vinblastine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 0.4 mg/kg every three weeks for four courses
Study: 6158370
Drug: Vinblastine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 0.3 mg/kg every three weeks for four courses
Study: 6158370
Drug: Vinblastine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every three weeks for four courses
Study: 6158370
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months
Study: 28115877
Drug: Intrathecal Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Morphine (Group M)
Study: 22190273
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1,000 mg calcium carbonate plus 400 IU vitamin D(3) daily)
Study: 17340636
Drug: S1 (gadolinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 (gadolinium as oral tagging agent and a gadolinium-water mixture for rectal filling)
Study: 17340636
Drug: S2 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: S2 (oral barium and water rectally)
Study: 17340636
Drug: S3 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: S3 (oral barium and air rectally)
Study: 16336763
Drug: Two protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two protease inhibitors (saquinavir + nelfinavir)
Study: 16336763
Drug: One protease
Normalized name: Sea anemone protease A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One protease inhibitor (saquinavir soft gel capsule)
Study: 18205965
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (CBT)
Study: 14626395
Drug: Preincisional periportal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional periportal infiltration with 20 mL of ropivacaine (10 mg/mL)
Study: 10711915
Drug: Nortriptyline maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline maintenance therapy (plasma levels 60-150 ng/mL) for up to 2 years
Study: 9352864
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.25 IU/kg body wt)
Study: 31442298
Drug: Ticagrelor-monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor-monotherapy
Study: 22886852
Drug: Atropine/scopolamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine/scopolamine mixture at 12.10/9.50 µg kg(‐1) body mass (BM)
Study: 22886852
Drug: Atropine/scopolamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine/scopolamine mixture at 0.37/0.29 and 1.22/0.95 µg kg(‐1) BM
Study: 22886852
Drug: Atropine/scopolamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine/scopolamine mixture at 0.12/0.10 µg kg(‐1) BM
Study: 22886852
Drug: Atropine/scopolamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine/scopolamine mixture (various doses)
Study: 21982669
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein ≥6.6 mg/L
Study: 16343498
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusion 20 units
Study: 8621132
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/d for 6 weeks)
Study: 6131624
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg orally
Study: 3977064
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 30 ml orally
Study: 29961998
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 to 4 mg
Study: 25755685
Drug: 13.3 mg/24
Normalized name: Exelon, 13.3 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.3 mg/24 h rivastigmine patch
Study: 23924050
Drug: 4.6 mg/24
Normalized name: Exelon, 4.6 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.6 mg/24 h rivastigmine patch
Study: 24257390
Drug: Cisatracurium +
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium + Albuterol
Study: 24257390
Drug: Rocuronium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium + Albuterol
Study: 15610805
Drug: Oral oxytetracycline
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxytetracycline plus topical placebo
Study: 15610805
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline plus topical placebo
Study: 15610805
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide plus oral placebo
Study: 15610805
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin and benzoyl peroxide in a combined formulation plus oral placebo
Study: 15610805
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin and benzoyl peroxide separately plus oral placebo
Study: 15610805
Drug: Erythromycin and
Normalized name: Erythromycin and zinc only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin and benzoyl peroxide separately versus combined formulation
Study: 15610805
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide versus combined formulation
Study: 12177686
Drug: Galantamine 16
Normalized name: galantamine 16 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 16 mg/day
Study: 9205760
Drug: Ebrotidine (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (150, 300, 400, 500, 600, 800 mg)
Study: 31917765
Drug: Double low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Double low-dose group (n = 35)
Study: 31917765
Drug: Standard-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose group (n = 32)
Study: 28787186
Drug: Tralokinumab 400
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab 400 mg
Study: 28787186
Drug: Tralokinumab 800
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab 800 mg
Study: 27391985
Drug: Inpatient general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient general psychiatric treatment
Study: 18931495
Drug: Erosion +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erosion + caries (EC) - cola drink 3 times/day + sucrose solution 8 times/day with plaque
Study: 18931495
Drug: Caries only
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries only (CO) - sucrose solution 8 times/day with plaque
Study: 14744417
Drug: Freshly prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freshly prepared patches
Study: 14744417
Drug: Previously prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously prepared and stored patches
Study: 6403546
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliomyelitis vaccine prepared from monkey kidney cells
Study: 6403546
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliomyelitis vaccine prepared from human diploid cells (MRC5)
Study: 31576697
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus durvalumab and tremelimumab
Study: 31576697
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus durvalumab
Study: 1442907
Drug: Localized cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized cold therapy to the cesarean section incision
Study: 22729756
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy (KT) using oscillating beds (TryaDyne Proventa, KCI)
Study: 18369092
Drug: Low-Fructose (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Fructose (0.3 g/min)
Study: 18369092
Drug: Medium-Fructose (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-Fructose (0.5 g/min)
Study: 18369092
Drug: High-Fructose (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fructose (0.7 g/min)
Study: 18369092
Drug: No-Fructose (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Fructose (0.0 g/min)
Study: 15787663
Drug: Pioglitazone up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone up to 45 mg once daily
Study: 15787663
Drug: Gliclazide up
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide up to 160 mg two times daily
Study: 2013140
Drug: Early hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early hospital discharge on day 4 after aggressive interventional therapy
Study: 25058803
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg methylprednisolone
Study: 25311285
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET), 50-minute session
Study: 15735106
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplement
Study: 15735106
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient supplement
Study: 15735106
Drug: Weekly multiple
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple micronutrient supplement with daily placebo
Study: 15735106
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo supplement
Study: 12898888
Drug: Basic dental
Normalized name: Basic Dental Emergency Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic dental care interventions focusing on prophylactics, education, and treatment
Study: 29684999
Drug: Nano copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano copper (100 mg/kg/day)
Study: 29684999
Drug: Copper sulfate
Normalized name: copper sulfate
DrugBank: Copper (DB09130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copper sulfate (CuSO4) (50, 100, and 200 mg/kg/day)
Study: 20681336
Drug: Progressive Self‐focus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Self‐focus Meditation (weekly 1‐hr. training sessions for 5 weeks)
Study: 19026808
Drug: Esmolol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol as first-line antihypertensive medication in the operating room
Study: 19026808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of esmolol and sodium nitroprusside (Nipride)
Study: 19026808
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications at discharge
Study: 1474178
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg adinazolam mesylate sustained release tablet
Study: 1474178
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg immediate release tablet
Study: 1474178
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intravenous adinazolam mesylate
Study: 6096154
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg/day)
Study: 29894287
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg before PCI)
Study: 29894287
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg before PCI)
Study: 25157768
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg plus carboplatin/paclitaxel (Arm A)
Study: 18853833
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel (AG)
Study: 15837412
Drug: Whole-body low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole-body low-dose multidetector row-CT (MDCT)
Study: 9888625
Drug: Triazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.75 mg
Study: 2507667
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg p.o. plus metoprolol 50 mg p.o.
Study: 2507667
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg p.o. plus i.m. scopolamine 0.006 mg/kg and morphine 0.2 mg/kg
Study: 320090
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no hormonal treatment)
Study: 27500908
Drug: Internal Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Family Systems (IFS) therapy